BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (BRESELIBET)

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy With Brentuximab Vedotin-ESHAP vs ESHAP in Patients With Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (Instead of Autologous Hematopoietic Stem Cell Transplantation) in Those Who Attained a Metabolic Complete Remission After Salvage Therapy

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

Study Overview

• Status: Recruiting
• Conditions: Hodgkin Lymphoma, Adult
• Intervention / Treatment: Drug: Induction without Brentuximab Vedotin; Drug: Consolidation with Brentuximab Vedotin; Drug: Induction with Brentuximab vedotin (BV)

Detailed Description

A phase IIb open label multi-center trial in patients with refractory / relapsed cHL.

Patients are randomized (1:1) to receive:

• ESHAP- BV (Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], high dose Ara-C [2 g/m2 IV, D5] and cisplatinum [25 mg/m2/day IV, D1-4] + BV [1.8 mg/kg IV, D1], every 21 days (3 cycles, q21 days).

Or

• ESHAP (Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], high dose Ara-C [2 g/m2 IV, D5] and cisplatinum [25 mg/m2/day IV, D1-4] (3 cycles, q21 days)

Stem cell collection will be performed in all patients according to institutional guidelines, but preferably after the first / second cycle of ESHAP-BV or ESHAP.

Patients attaining a mCR (Deauville 1, 2) after receiving 3 cycles of ESHAP-BV, will receive up to 13 cycles of BV consolidation (administered every 3 weeks, over 39 weeks).

Patients who were randomized to ESHAP and attained a mCR after receiving 3 cycles will receive up to 16 cycles of BV (same dosage and time intervals).

Patients who attained less than mCR following ESHAP-BV/ESHAP they will be taken out of the trial and will be treated according to their physician's clinical decision. However, they will be followed in order to evaluate their clinical outcome in terms of ORR, CR rate, TTNT2 and OS, that will be analyzed the study separately.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: lucia palacios, MSc; Phone Number: +18599134526; Email: ensayosclinicos01@geltamo.com
• Study Contact Backup: Name: Angel Cedillo, MSc; Phone Number: +34 91315780; Email: sc@geltamo.com

Study Locations

• Spain
  • A Coruña, Spain, 15006
    • Recruiting
    • Complexo Hospitalario Universitario A Coruña
  • BArcelona, Spain, 08041
    • Recruiting
    • Hospital de la Santa Creu i Sant Pau
  • Barcelona, Spain, 08036
    • Recruiting
    • Hospital Clinic de Barcelona
  • Barcelona, Spain, 08908
    • Recruiting
    • Institut Català d'Oncologia - Hospital Duran i Reynals
  • Barcelona, Spain, 08908
    • Recruiting
    • Institut Català d'Oncologia
  • Bilbao, Spain, 48903
    • Recruiting
    • Hospital Universitario de Cruces
  • Granada, Spain, 18014
    • Recruiting
    • Hospital Universitario Virgen de las Nieves
  • MAdrid, Spain, 28041
    • Recruiting
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28007
    • Recruiting
    • Hospital General Universitario Gregorio Marañon
  • Madrid, Spain, 28034
    • Recruiting
    • Hospital Ramon y Cajal
  • Madrid, Spain, 28040
    • Recruiting
    • Hospital Universitario Fundación Jiménez Díaz
  • Murcia, Spain, 30008
    • Recruiting
    • Hospital General Universitario J.M. Morales Meseguer
  • Salamanca, Spain, 37007
    • Recruiting
    • Hospital Universitario de Salamanca
  • Sevilla, Spain, 41013
    • Recruiting
    • Hospital Universitario Virgen del Rocio
  • Valencia, Spain, 46026
    • Recruiting
    • Hospital Universitario Y Politécnico La Fe
  • Valencia, Spain
    • Recruiting
    • Hospital Clinico Universitario de Valencia
  • Asturias
    • Oviedo, Asturias, Spain, 33011
      • Recruiting
      • Hospital Universitario Central de Asturias
  • Barceolna
    • Barcelona, Barceolna, Spain, 08916
      • Recruiting
      • Institut Català d'Oncologia - Hospital Germans Trias i Pujol
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Recruiting
      • Hospital Universitario Marques de Valdecilla

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Patients with classical HL CD30+ confirmed histologically (either at the time of diagnosis / at the time of first relapse) will be included in the trial

• Male or female patients 18 to 65 years of age
• Voluntary written informed consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
• Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
• Male patients, even if surgically sterilized, (i.e., status post-vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
• ECOG 0 to 2
• Measurable disease at time of enrolment (lymphadenopathy/ extranodal mass of at least 1.5 cm)
• No evidence of neuropathy grade ≥2
• Clinical laboratory values as specified in the protocol below within 7 days before the first dose of study drug

Exclusion Criteria:

• Lymphocyte predominant nodular Hodgkin's lymphoma
• Prior treatment with brentuximab vedotin
• Female patient who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.
• Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
• Symptomatic neurologic disease compromising normal activities of daily living or requiring medic
• Any sensory or motor peripheral neuropathy greater than or equal to Grade 2
• Known history of any of the following cardiovascular conditions defined in the protocol
• Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
• Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives (or 28 days if the half-lives are unknown) of last dose of that prior treatment
• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
• Known human immunodeficiency virus (HIV) positive
• Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
• Focal radiation therapy within 30 days prior to study recruitment
• Major surgery within 28 days prior to randomization
• Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
• Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Induction ESHAP; 3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]	Drug: Induction without Brentuximab Vedotin; 3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy; Other Names: ESHAP treatment as salvage therapy; Drug: Consolidation with Brentuximab Vedotin; Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days); Other Names: Adcetris treatment as consolidation
Experimental: Induction BV-ESHAP; 3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]	Drug: Consolidation with Brentuximab Vedotin; Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days); Other Names: Adcetris treatment as consolidation; Drug: Induction with Brentuximab vedotin (BV); 3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV; Other Names: Adcetris treatment + ESHAP as salvage therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PET-CT result	PET-CT negative, Deauville scores 1 and 2	4-6 weeks after the Cycle 3 started (each cycle is 21 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
progression-free survival (PFS)	Evaluation of patient without progression of disease	At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
Duration of response	Lenght of time between date of evidence response and progression of disease or death	At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
Overall Survival (OS)	Time from entry onto the clinical trial (random assignment in a phase III study) until death as a result of any cause.	At the end of two years of last dose of consoldation Brentuximab VEdotin treatment
Duration of response (DOR)	Time from first documentation of CR or PR to disease progression	At the end of two years of last dose of consoldation Brentuximab VEdotin treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability	AEs, fertility,infections, and secondary malignancies	At the end of the 3 years of of last dose of consoldation Brentuximab VEdotin treatment

Collaborators and Investigators

• Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
• Investigators: Principal Investigator: Anna Sureda, PhD, Institut Catala d'Oncologia, Hospital Duran i Reynals

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2020
• Primary Completion (Estimated): August 30, 2026
• Study Completion (Estimated): August 30, 2026

Study Registration Dates

• First Submitted: May 4, 2020
• First Submitted That Met QC Criteria: May 5, 2020
• First Posted (Actual): May 7, 2020

Study Record Updates

• Last Update Posted (Estimated): February 26, 2024
• Last Update Submitted That Met QC Criteria: February 23, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Hodgkin Disease; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Immunoconjugates; Immunotoxins; Antibodies, Monoclonal; Brentuximab Vedotin
• Other Study ID Numbers: GELTAMO18-HL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No